Absci is trading at $7.65 (down 5.2%) as it extends a pullback following a parabolic rally and a sharp drop in last Thursday’s extended session.
- The recent downward pressure is attributed to profit-taking and the market's digestion of equity-offering dilution.
- The decline aligns with broader biotech sector weakness rather than any fresh company-specific shocks today.